LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete. Credit: LumiraDx / PRNewswire.

LumiraDx has obtained CE mark for two Fast Lab Solutions multiplex tests, SARS-CoV-2 & Flu A/B RNA STAR Complete and Dual-Target SARS-CoV-2 STAR Complete.

The new LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete multiplex assay has been designed to simultaneously detect and differentiate SARS-CoV-2, influenza A and influenza B viruses.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It uses nasopharyngeal or anterior nasal swabs collected from individuals who are suspected of Covid-19 and/or influenza by their healthcare provider.

Compared to high sensitivity RT-PCR tests, the multiplex assay has a positive percent agreement (PPA) of 92.3% for influenza A, 95.7% for influenza B and 94.1% for SARS-CoV-2 in symptomatic individuals.

It has a negative percent agreement (NPA) of more than 99.5%.

See Also:

The LumiraDx Dual-Target SARS-CoV-2 STAR Complete multiplex assay is intended for the detection of nucleic acid from two gene markers to identify the presence of SARS-CoV-2 from nasopharyngeal or anterior nasal swabs from Covid-19 suspected individuals.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company stated that the test has been developed to meet certain regulatory requirements in many regions that need two or more targets for Covid-19 diagnosis.

It also noted that the multiplex assay was demonstrated to have an NPA of 100% and PPA of 97.7% for SARS-CoV-2 in symptomatic individuals when compared to a high sensitivity RT-PCR.

The two tests are developed using the company’s qSTAR single-step nucleic acid extraction and amplification technology and provide results within 20 minutes.

LumiraDx Fast Lab Solutions president Sanjay Malkani said: “As the pandemic persists, we remain focused on bringing to market high-quality molecular diagnostics that further remove testing barriers and enhance laboratory operations.

“We are pleased to demonstrate unrivalled innovation with direct method, high-throughput, highly sensitive assays for open molecular platforms – with results available in 20 minutes – and the added benefit of accurately detecting influenza and Covid-19 from a single sample.”